Dichlororibobenzimidazole

Dichlororibobenzimidazole

SCHEMBL7812697

OC[C@@H]1O[C@H](n2cnc3cc(Cl)c(Cl)cc32)[C@@H](O)[C@H]1O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.54
LMNA P02545 2/20 0.54
KDM4E B2RXH2 3/20 0.54
PKM P14618 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
ALDH1A1 P00352 2/20 0.51
HTT P42858 2/20 0.51
BLM P54132 2/20 0.51
GMNN O75496 1/20 0.51
NFKB1 P19838 1/20 0.51
DNMT1 P26358 1/20 0.51
THPO P40225 1/20 0.51
MTOR P42345 1/20 0.51
RAB9A P51151 1/20 0.51
HBB P68871 1/20 0.51
PMP22 Q01453 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dichlororibobenzimidazole SCHEMBL29352589 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL8367472 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL1535249 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL8368991 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL23815679 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL362387 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL23982247 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL20419020 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL8368931 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6
Dichlororibobenzimidazole SCHEMBL29533962 1.00 TP53 (0.54) TP53LMNAKDM4EPKMHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180179594-A1 MULTIPLE SYSTEM ATROPHY AND THE TREATMENT THEREOF PARKINSON'S INSTITUTE 2018-06-28 US disclosed
US-20180179594-A1 MULTIPLE SYSTEM ATROPHY AND THE TREATMENT THEREOF PARKINSON'S INSTITUTE 2018-06-28 US disclosed
US-6307043-B1 FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS GLAXO WELLCOME INC. 2001-10-23 US disclosed
US-20010003744-A1 Therapeutic compounds CHAMBERLAIN STANLEY DAWES (US) 2001-06-14 US disclosed
US-6077832-A FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION GLAXO WELLCOME INC. (US) 2000-06-20 US disclosed
EP-0769017-B1 THERAPEUTIC COMPOUNDS WELLCOME FOUND (GB) 2000-05-24 EP disclosed
US-5998605-A Antiviral benzimidazole nucleoside analogues and method for their preparation GLAXO WELLCOME INC. (US) 1999-12-07 US disclosed
WO-1996001833-A1 THERAPEUTIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003744-A1 Therapeutic compounds ZC3HAV1, HAVCR2, EIF2AK2 TP53 650/4885LMNA 3592/4885KDM4E 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.